跳至主要内容
临床试验/JPRN-UMIN000025784
JPRN-UMIN000025784已完成未知

Safety and efficacy of Grazoprevir and Elbasvir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infection - Grazoprevir/Elbasvir therapy for hemodialyzed patients

Graduate School of Medicine, Hokkaido University0 个研究点目标入组 60 人开始时间: 2017年1月21日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1 Patients with a past history of hypersensitivity to HCV protease inhibitors and NS5A inhibitors 2 Patients with serious liver dysfunction (Child-Pugh Class B or C) 3 Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4 Patients who have malignant tumors, including hepatoma, at the start of treatment 5 Patients on treatment with drugs listed in the contraindications for coadministration in the package insert (e.g., some antifungals, some antiepileptics, and human immunodeficiency virus (HIV) protease inhibitors) 6 Patients with albumin <3.0 g/dL 7 Other patients judged to be inappropriate to participate in the study by the primary physician

研究者

发起方
Graduate School of Medicine, Hokkaido University

相似试验

Safety and efficacy of Grazoprevir and Elbasvir... | 临床试验